Michael Balkin
Michael Balkin's purchase track record
How the stock did after each of Michael Balkin's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/9/2026 | HRZN | $434K | +17.4% | pending | — |
| 12/16/2024 | HRZN | $171K | +11.8% | -7.8% | -0.7% |
| 8/5/2024 | HRZN | $106K | -12.0% | -8.2% | +15.6% |
| 1/28/2022 | PIII | $72K | +29.1% | +4.5% | -6.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
PIII appoints new Chief Clinical Officer. P3 Health Partners announced the appointment of a new Chief Clinical Officer. The executive will oversee clinical operations and strategy for the company. This addition brings additional expertise as the firm pursues its growth plans. The stock is currently trading with a low RSI and near its recent support level.
Transaction History
| HRZN | ▲ Buy | Open Market | 100,000 | $434K | 6/9/2026 | View on chart |
| HRZN | ▲ Buy | Grant | 93,527 | — | 4/14/2026 | View on chart |
| HRZN | ▲ Buy | Grant | 93,527 | — | 4/14/2026 | View on chart |
| HRZN | ▲ Buy | Open Market | 20,000 | $171K | 12/16/2024 | View on chart |
| HRZN | ▲ Buy | Open Market | 10,000 | $106K | 8/5/2024 | View on chart |
| PIII | ▲ Buy | Open Market | 15,000 | $72K | 1/28/2022 | View on chart |
| PIII | ▼ Sell | Other | 6,843,525 | — | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
TriplePoint Venture Growth faces potential further challenges
A recent analysis suggests that TriplePoint Venture Growth may face continued difficulties. This is relevant to Horizon Technology Finance as a peer in the specialty finance sector, where market sentiment can influence broader group performance. The stock currently trades near its 52-week low, with a high dividend yield and a P/E ratio significantly above the sector average.
TriplePoint Venture Growth faces potential further challenges. A recent analysis suggests that TriplePoint Venture Growth may face continued difficulties. This is relevant to Horizon Technology Finance as a peer in the specialty finance sector, where market sentiment can influence broader group performance. The stock currently trades near its 52-week low, with a high dividend yield and a P/E ratio significantly above the sector average.